Pfizer Inc. today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, ...
These maps display data from a single computer model. Please note they may be different to the Bureau's official products including local and coastal waters forecasts, tropical cyclone warnings, and ...